News und Analysen
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210502005042/en/
Figure 1. Evolution of BCVA in ND4-LHON patients
NANOBIOTIX Announces First Quarter Operational and Financial Updates
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to
NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene Reports Business Update and End Q1 2021 Financial Position
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
BOIRON : 2021 fisrt quarter activity
(Unaudited data)
In thousands of euros 2021 2020 Variation at current exchange rates Variation at constant exchange rates France 51,518 72,820 -29.3% -29.3%
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Strasbourg, France, April 12, 2021, 05:45 pm CET – Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary
NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’), a late-stage clinical biotechnology company pioneering physics-based approaches to
Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2020 and
Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the expansion of a
BOIRON : 2020 results
The Board of Directors of BOIRON, at its meeting on March 10, 2021 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31
GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
NANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand
NANOBIOTIX: Preclinical Data Presented at First AACR Virtual Special Conference on Radiation Science and Medicine Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance, Promotes Strong Abscopal Effect and Long-Term Anti-Cancer Memory
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in
Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that members of Transgene’s management
Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
NANOBIOTIX 2020 Q4 and Annual Revenues
Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies